lateonset
sever
pneumonia
allogen
hematopoiet
stem
cell
transplant
prognost
factor
treatment
transpl
infect
di
right
reserv
abstract
background
studi
aim
evalu
prognost
factor
associ
treatment
lateonset
sever
pneumonia
losp
patient
underw
allogen
hematopoiet
stem
cell
transplant
allohsct
method
fifti
consecut
patient
underw
nontcelldeplet
allohsct
peke
univers
institut
hematolog
met
criterion
losp
allohsct
enrol
result
median
time
allohsct
occurr
losp
day
twentyeight
patient
harbor
pathogen
infecti
losp
ilosp
wherea
harbor
pathogen
noninfecti
losp
nilosp
surviv
rate
losp
patient
patient
smoke
allohsct
vs
p
male
gender
vs
p
lower
surviv
rate
patient
lower
bronchoalveolar
lavag
fluid
balf
neutrophil
percentag
higher
surviv
rate
rel
higher
balf
neutrophil
percentag
vs
p
surviv
rate
patient
ilosp
lower
patient
nilosp
vs
p
patient
given
late
week
losp
diagnosi
lowdos
methylprednisolon
mp
therapi
mgkgday
best
surviv
rate
multivari
analysi
nonsmok
allohsct
late
lowdos
mp
therapi
significantli
associ
better
surviv
losp
conclus
losp
sever
complic
allohsct
correct
time
corticosteroid
dosag
context
broadspectrum
antimicrobi
therapi
might
improv
outcom
patient
losp
allogen
hematopoiet
stem
cell
transplant
allohsct
effect
treatment
hematolog
malign
mani
patient
cure
achiev
longterm
remiss
although
transplant
techniqu
progress
significantli
treatmentrel
mortal
continu
serious
influenc
surviv
patient
undergon
allohsct
sever
pulmonari
complic
consid
among
worst
complic
associ
procedur
infecti
noninfecti
pulmonari
complic
found
hsct
recipi
respect
sever
pulmonari
complic
therefor
account
signific
percentag
death
transplant
pulmonari
complic
infecti
noninfecti
commonli
occur
within
month
transplant
increas
number
patient
achiev
longterm
surviv
attent
given
lateonset
pulmonari
complic
month
transplant
chen
et
al
observ
median
followup
year
patient
develop
least
episod
pneumonia
transplant
cumul
incid
first
pneumonia
episod
year
rang
observ
patient
suffer
acut
sever
pneumonia
month
allohsct
patient
common
featur
rapid
progress
absenc
pathogen
high
mortal
liu
et
al
report
studi
patient
experienc
lateonset
sever
pneumonia
losp
allohsct
incid
losp
among
affect
patient
test
posit
pathogen
die
despit
receiv
comprehens
therapi
suggest
losp
might
sever
complic
affect
clinic
outcom
allohsct
recipi
howev
rel
studi
address
prognost
factor
associ
treatment
losp
allohsct
retrospect
studi
therefor
aim
evalu
prognost
factor
treatment
patient
losp
undergo
human
leukocyt
antigen
hla
relat
donor
hsct
consecut
patient
underw
nontcelldeplet
allohsct
peke
univers
institut
hematolog
june
june
enrol
met
criteria
use
defin
losp
allohsct
underw
chest
computer
tomographi
ct
bronchoalveolar
lavag
bal
patient
experienc
sever
pneumonia
within
month
hsct
receiv
ct
bal
exclud
total
patient
enrol
undergon
hlaident
sibl
donor
hsct
hlahaploident
relat
donor
haplord
hsct
respect
tabl
final
followup
visit
endpoint
analysi
conduct
septemb
inform
consent
obtain
patient
studi
conduct
accord
declar
helsinki
studi
protocol
approv
ethic
committe
peke
univers
peopl
hospit
five
includ
patient
previous
report
liu
et
al
precondit
compris
cytarabin
busulfan
mgkgday
day
cyclophosphamid
gm
day
day
simustin
mgm
day
cytarabin
administ
gm
day
day
haplord
group
gm
day
day
ident
sibl
donor
group
rabbit
antithymocyt
globulin
mgkg
day
day
thymoglobulin
sanofi
franc
administ
haplord
group
granulocyt
colonystimul
factormobil
fresh
unmanipul
harvest
bone
marrow
peripher
blood
infus
recipi
day
collect
granulocyt
colonystimul
factor
lgkgday
subcutan
administ
haplord
hsct
recipi
day
transplant
white
blood
cell
count
exceed
cellsl
consecut
day
addit
patient
receiv
cyclosporin
mycophenol
mofetil
shortterm
methotrex
graftversushost
diseas
gvhd
prophylaxi
comorbid
hsct
recipi
assess
accord
hematopoiet
cell
transplantationspecif
comorbid
index
donor
select
hla
type
stem
cell
harvest
procedur
describ
elsewher
patient
hospit
room
high
effici
particleair
filter
week
day
time
neutrophil
recoveri
achiev
receiv
antibiot
prophylaxi
oral
trimethoprimsulfamethoxazol
prevent
pneumocysti
jirovecii
infect
day
patient
also
receiv
fluconazol
candida
albican
day
acyclovir
herpex
simplex
viru
hsv
varicella
zoster
viru
vzv
day
time
cyclosporin
discontinu
ciprofloxacin
intestin
decontamin
ganciclovir
mgkg
administ
intraven
iv
twice
daili
day
prophylaxi
cytomegaloviru
cmv
infect
infect
surveil
treatment
protocol
use
institut
previous
describ
elsewher
follow
major
criteria
use
defin
losp
invas
mechan
ventil
ii
septic
shock
requir
vasopressor
follow
minor
criteria
use
respiratori
rate
breathsmin
ii
arteri
oxygen
pressurefract
inspir
oxygen
ratio
iii
multilobar
infiltr
iv
confus
disorient
v
uremia
blood
urea
nitrogen
level
mgdl
vi
leukopenia
result
sole
infect
white
blood
cell
count
cellsl
vii
thrombocytopenia
platelet
count
cellsl
viii
hypothermia
core
temperatur
ix
hypotens
requir
aggress
fluid
resuscit
evid
cardiogen
pulmonari
edema
observ
accord
clinic
find
central
venou
pressur
measur
cardiac
echocardiographi
patient
experienc
pneumonia
month
allohsct
exhibit
major
criterion
minor
criteria
diagnos
losp
patient
underw
ct
bal
blood
bal
fluid
balf
sampl
routin
subject
follow
test
gram
stain
fungal
stain
grocottgomori
methenaminesilv
stain
acidfast
bacilli
stain
ii
cytolog
examin
iii
bacteri
fungal
cultur
iv
realtim
polymeras
chain
reaction
pcr
revers
transcriptionpcr
assay
detect
atyp
bacteria
eg
legionella
speci
mycoplasma
pneumonia
chlamydia
pneumonia
herpesvirus
hsv
type
posit
cmv
ebv
target
pathogen
load
determin
quantit
pcr
patient
losp
receiv
oxygen
therapi
empir
broadspectrum
antimicrobi
therapi
cover
pseudomona
aeruginosa
methicillinresist
staphylococcu
aureu
aspergillu
itraconazol
mg
iv
hourli
h
mg
iv
daili
voriconazol
mgkg
iv
h
mgkg
iv
caspofungin
load
dose
mg
iv
daili
micafungin
mg
iv
daili
liposom
amphotericin
b
mgkg
iv
daili
amphotericin
b
deoxychol
mgkg
iv
daili
p
jiroveciii
corticosteroid
patient
receiv
donor
lymphocyt
infus
dli
patient
increas
hypoxemia
despit
receiv
high
level
supplement
nasal
oxygen
transfer
intens
care
unit
icu
requir
noninvas
ventil
endotrach
intub
highrisk
patient
defin
follow
acut
leukemia
patient
first
second
complet
remiss
cytogenet
marker
poorrisk
includ
ii
patient
complet
remiss
third
complet
remiss
iii
patient
partial
remiss
nonremiss
state
relaps
hsct
iv
patient
chronic
myelogen
leukemia
beyond
first
chronic
phase
patient
stratifi
standardrisk
categori
neutrophil
engraft
defin
first
day
absolut
neutrophil
count
l
consecut
day
platelet
engraft
defin
first
day
platelet
count
l
consecut
day
without
transfus
gvhd
diagnos
accord
accept
intern
criteria
overal
surviv
os
defin
time
pneumonia
death
caus
date
last
contact
infecti
losp
ilosp
defin
identif
pathogen
blood
andor
balf
sampl
noninfecti
losp
nilosp
defin
absenc
pathogen
blood
andor
balf
sampl
data
censor
time
death
last
avail
followup
continu
variabl
compar
use
mannwhitney
utest
categor
variabl
compar
use
chisquar
test
fisher
exact
test
kaplanmei
method
use
estim
probabl
os
landmark
analysi
perform
assess
surviv
patient
losp
posttranspl
day
losp
diagnosi
defin
landmark
day
os
calcul
landmark
day
death
caus
date
last
contact
potenti
prognost
factor
os
losp
evalu
univari
multivari
analys
use
cox
proport
hazard
regress
backwardstepwis
model
select
approach
independ
variabl
pvalu
sequenti
exclud
model
level
signific
set
p
report
pvalu
base
test
data
analys
conduct
spss
softwar
spss
inc
chicago
illinoi
usa
breathsmin
one
patient
exhibit
confus
patient
experienc
septic
shock
thirtysix
patient
transfer
icu
requir
noninvas
ventil
requir
endotrach
intub
thirtyfour
patient
die
treatment
die
losp
median
durat
losp
diagnosi
death
day
remain
patient
cure
treatment
die
relaps
day
losp
os
rate
day
losp
fig
patient
smoke
allohsct
vs
p
male
gender
vs
p
fig
lower
surviv
rate
howev
prehsct
lung
function
test
influenc
os
rate
losp
patient
vs
median
vs
p
dlco
vs
median
vs
p
patient
underw
chest
ct
patient
underw
multipl
chest
ct
examin
result
initi
scan
includ
analysi
patchi
appear
common
present
n
follow
groundglass
opac
n
pleural
effus
n
fibrou
stripe
n
consolid
opac
n
nodul
n
chest
ct
characterist
compar
nilosp
ilosp
group
tabl
patient
underw
bal
patient
underw
multipl
bal
procedur
initi
result
includ
analysi
median
balf
cell
subset
valu
compar
nilosp
ilosp
group
tabl
patient
die
losp
significantli
higher
balf
neutrophil
count
survivor
losp
cellsl
vs
cellsl
p
patient
higher
balf
neutrophil
percentag
use
median
cutoff
point
significantli
lower
surviv
rate
patient
vs
p
figur
pathogen
identifi
blood
andor
balf
sampl
patient
ilosp
posit
blood
sampl
posit
balf
sampl
simultan
posit
blood
balf
sampl
fifteen
patient
infect
caus
singl
multipl
organ
respect
tabl
cmv
common
establish
viru
identifi
simultan
plasma
balf
sampl
patient
median
plasma
balf
viral
load
copi
copi
respect
second
common
viru
ebv
identifi
simultan
plasma
balf
sampl
patient
median
plasma
balf
viral
load
copi
copi
respect
third
common
viru
rsv
identifi
simultan
plasma
balf
sampl
patient
common
bacterium
acinetobact
baumannii
follow
p
aeruginosa
staphylococcu
epidermidi
enterococcu
faecium
sever
multiresist
bacteria
recov
baumannii
n
p
aeruginosa
n
e
faecium
n
candida
identifi
balf
patient
might
suggest
bystand
organ
tabl
nilosp
group
patient
could
classifi
idiopath
pneumonia
syndrom
ip
organ
pneumonia
bronchiol
obliteran
syndrom
respect
mechan
ventil
rate
higher
median
mechan
ventil
durat
longer
ilosp
group
fig
patient
losp
receiv
oxygen
therapi
empir
broadspectrum
antimicrobi
therapi
fortytwo
patient
receiv
trimethoprimsulfamethoxazol
initi
antifung
drug
use
treatment
case
follow
caspofungin
case
itraconazol
case
voriconazol
case
amphotericin
b
case
micafungin
case
three
patient
receiv
target
antifung
therapi
other
receiv
empir
antifung
therapi
thirteen
patient
receiv
combin
antifung
therapi
fortyfour
patient
receiv
antiviru
therapi
iv
ganciclovir
foscarnet
sodium
patient
iv
ribavirin
patient
rsv
n
parainfluenza
viru
n
oral
oseltamivir
patient
ten
patient
receiv
combin
antivir
therapi
patient
receiv
ribavirin
therapi
tend
better
os
vs
p
figur
wherea
associ
observ
antiinfect
therapi
outcom
data
shown
patient
receiv
corticosteroid
therapi
initi
methylprednisolon
mp
dose
mgkgday
median
time
losp
diagnosi
mp
therapi
day
patient
initi
given
lowdos
mp
mgkgday
better
os
rate
losp
patient
initi
given
highdos
mp
mgkgday
addit
os
rate
losp
patient
given
late
mp
therapi
week
losp
diagnosi
better
patient
given
earli
mp
therapi
week
losp
diagnosi
patient
receiv
late
lowdos
mp
therapi
best
outcom
fig
eight
patient
receiv
dli
median
time
losp
diagnosi
dli
day
median
cell
dose
cell
kg
dli
improv
surviv
among
patient
losp
figur
femal
gender
nonsmok
allohsct
lower
balf
neutrophil
percentag
use
median
cutoff
point
nilosp
late
lowdos
mp
therapi
associ
better
os
losp
univari
analysi
multivari
analysi
nonsmok
allohsct
late
lowdos
mp
therapi
significantli
associ
better
os
losp
tabl
although
transplant
techniqu
progress
significantli
losp
allohsct
continu
serious
influenc
patient
surviv
studi
os
rate
losp
despit
use
sever
therapi
observ
patient
smoke
allohsct
poorer
outcom
balf
neutrophil
percentag
might
predict
outcom
patient
losp
addit
correct
mp
dose
time
might
improv
outcom
patient
studi
blood
andor
balf
sampl
patient
posit
pathogen
indic
infect
may
import
caus
losp
chen
et
al
also
observ
infect
import
caus
lateonset
pneumonia
allohsct
addit
pathogen
detect
patient
might
thu
meet
diagnost
criteria
ip
suggest
alloimmun
reaction
play
import
role
develop
losp
howev
seo
et
al
report
half
patient
previous
diagnos
ip
found
harbor
pathogen
accord
current
avail
diagnost
method
suggest
infect
remain
import
caus
losp
addit
infecti
agent
trigger
autoimmun
via
differ
mechan
mani
studi
observ
infect
particularli
viral
infect
trigger
graftversushost
gvh
reaction
therefor
suggest
immun
reaction
patient
nilosp
might
also
occult
infecti
etiolog
although
pathogen
detect
balf
like
repres
shed
pulmonari
pathogen
rather
invas
diseas
observ
higher
cmv
ebv
load
balf
plasma
patient
losp
might
ill
undergo
invas
examin
eg
biopsi
histolog
confirm
addit
seo
et
al
observ
ip
patient
detect
pathogen
significantli
wors
os
rate
compar
patient
without
pathogen
accord
result
therefor
correct
method
identifi
pathogen
blood
andor
balf
might
critic
improv
outcom
patient
losp
observ
median
durat
losp
diagnosi
death
day
also
observ
median
valu
oxygen
index
high
losp
patient
need
mechan
ventil
suggest
losp
progress
rapidli
acut
respiratori
distress
syndrom
occur
patient
therefor
strategi
empir
broadspectrum
antimicrobi
therapi
administr
reason
addit
observ
initi
corticosteroid
therapi
dosag
time
associ
outcom
patient
losp
notabl
earli
highdos
mp
therapi
improv
outcom
hypothes
benefit
gain
corticosteroid
administr
sever
pneumonia
might
due
reduc
proinflammatori
cytokin
product
downregul
leukocyt
adhes
protein
express
prevent
excess
alveolar
collagen
deposit
howev
infect
may
import
caus
losp
highdos
mp
help
elimin
pathogen
addit
secondari
infect
might
associ
highdos
mp
therapi
mani
studi
found
lowdos
corticosteroid
therapi
may
improv
outcom
patient
sever
pneumonia
systemat
review
lamontagn
et
al
treatment
corticosteroid
dosag
equival
mgkg
day
mp
associ
lower
hospit
mortal
patient
sever
pneumonia
tang
et
al
found
mp
dosag
mgkgday
equival
associ
improv
mortal
morbid
outcom
without
increas
advers
reaction
patient
sever
pneumonia
observ
better
surviv
rate
among
patient
losp
treat
lowdos
mp
mgkgday
addit
mention
immun
reaction
might
also
occult
infecti
etiolog
could
play
import
role
develop
losp
although
meduri
et
al
observ
mp
use
earli
sever
acut
respiratori
distress
syndrom
associ
signific
improv
pulmonari
extrapulmonari
organ
dysfunct
reduct
durat
mechan
ventil
icu
length
stay
observ
patient
receiv
mp
therapi
within
week
losp
diagnosi
poor
outcom
specul
earli
mp
therapi
might
lead
loss
infect
control
may
thu
worsen
situat
case
losp
allohsct
wherein
pathogen
clear
use
effect
antiinfect
treatment
infectionrel
immun
reaction
remain
corticosteroid
therapi
could
improv
patient
outcom
thu
import
find
underscor
corticosteroid
therapi
use
patient
losp
allohsct
observ
viral
infect
might
import
caus
losp
howev
identifi
effect
treatment
viral
infect
donor
leukocyt
usual
contain
cytotox
cell
presensit
variou
virus
dli
might
potenti
treatment
viral
infect
allohsct
liu
et
al
observ
among
patient
losp
receiv
dli
surviv
end
followup
howev
studi
dli
improv
outcom
patient
losp
specul
dli
could
trigger
gvh
effect
might
exacerb
immunerel
lung
injuri
could
also
lead
myelosuppress
secondari
infect
sever
factor
also
associ
os
patient
losp
exampl
observ
femal
patient
losp
better
os
similarli
schwartz
et
al
show
male
gender
associ
diminish
surviv
idiopath
pulmonari
fibrosi
might
result
higher
frequenc
smoker
among
male
patient
ie
smoker
studi
male
smoke
hsct
independ
risk
factor
wors
surviv
multivari
analysi
addit
patient
higher
balf
neutrophil
percentag
wors
os
sever
studi
observ
higher
balf
neutrophil
percentag
associ
poor
outcom
infecti
noninfecti
lung
injuri
patient
therefor
suggest
overzeal
neutrophil
activ
might
result
sever
alveolar
damag
result
releas
cytotox
immun
cellactiv
agent
studi
sever
limit
first
retrospect
studi
rel
small
number
patient
losp
might
influenc
accuraci
find
second
might
underestim
occurr
ilosp
studi
number
pathogen
could
test
rel
small
third
could
detect
load
virus
except
cmv
ebv
therefor
could
identifi
associ
viru
load
outcom
losp
final
larg
number
differ
treatment
administ
treat
patient
ilosp
nilosp
group
introduc
heterogen
justif
gener
conclus
regard
advantag
given
late
lowdos
mp
therapi
respect
clinic
outcom
patient
losp
futur
prospect
multicent
studi
provid
inform
prognost
factor
treatment
losp
allohsct
summari
observ
losp
sever
complic
allohsct
patient
smoke
allohsct
wors
surviv
rate
correct
dosag
time
mp
context
broadspectrum
antimicrobi
therapi
could
improv
outcom
patient
losp
addit
support
inform
may
found
onlin
support
inform
tab
articl
figur
clinic
outcom
lateonset
sever
pneumonia
accord
bronchoalveolar
lavag
fluid
balf
neutrophil
lymphocyt
b
percentag
figur
clinic
outcom
lateonset
sever
pneumonia
accord
patient
without
ribavirin
b
without
donor
lymphocyt
infus
dli
